Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Fate Therapeutics to Present at Upcoming Investor Conferences
08:00am, Thursday, 11'th Nov 2021
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2021 Results - Earnings Call Transcript
12:29am, Friday, 05'th Nov 2021
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2021 Results - Earnings Call Transcript
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
06:19pm, Thursday, 04'th Nov 2021
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 1.72% and 64.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
3 Biotech Stocks to Watch Now
11:07am, Tuesday, 12'th Oct 2021
Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
08:01am, Friday, 01'st Oct 2021
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
08:19am, Tuesday, 14'th Sep 2021
Positive news versus poor clinical trial results may determine the future of Fate Therapeutics.
Cathie Wood Makes Adjustments to Portfolio in August
12:47pm, Monday, 13'th Sep 2021
Catherine Wood (Trades, Portfolio) disclosed last week her firm, ARK Investment Management, made a number of changes to its portfolio in August.
Fate Therapeutics to Present at Upcoming Investor Conferences
04:01pm, Thursday, 02'nd Sep 2021
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Why Fate Therapeutics Stock Is Sliding Today
11:57am, Friday, 20'th Aug 2021
The positive results the company announced after the bell yesterday didn't meet some lofty expectations.
Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response
06:36am, Friday, 20'th Aug 2021
Fate Therapeutics Inc (NASDAQ: FATE) revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed / refractory B-cell lymphoma. At the 2021 American Society of Clinical Oncol
10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with R
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues
12:56pm, Thursday, 05'th Aug 2021
FATE reports a wider loss on increased R&D expenses in the second quarter.
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2021 Results - Earnings Call Transcript
11:25pm, Wednesday, 04'th Aug 2021
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2021 Results - Earnings Call Transcript
Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus
Did You See What Cathie Wood Bought on Wednesday?
11:40am, Thursday, 22'nd Jul 2021
ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.
